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Abstract
Introduction: Community-acquired pneumonia (CAP) requiring intensive care unit (ICU) admission remains a
severe medical condition, presenting ICU mortality rates reaching 30%. The aim of this study was to assess the
value of different patterns of C-reactive protein (CRP)-ratio response to antibiotic therapy in patients with severe
CAP requiring ICU admission as an early maker of outcome.
Methods: In total, 191 patients with severe CAP were prospectively included and CRP was sampled every other
day from D1 to D7 of antibiotic prescription. CRP-ratio was calculated in relation to D1 CRP concentration. Patients
were classified according to an individual pattern of CRP-ratio response with the following criteria: fast response -
when D5 CRP was less than or equal to 0.4 of D1 CRP concentration; slow response - when D5 CRP was > 0.4 and
D7 less than or equal to 0.8 of D1 CRP concentration; nonresponse - when D7 CRP was > 0.8 of D1 CRP
concentration. Comparison between ICU survivors and non-survivors was performed.
Results: CRP-ratio from D1 to D7 decreased faster in survivors than in non-survivors (p = 0.01). The ability of CRP-
ratio by D5 to predict ICU outcome assessed by the area under the ROC curve was 0.73 (95% Confidence Interval,
0.64 - 0.82). By D5, a CRP concentration above 0.5 of the initial level was a marker of poor outcome (sensitivity
0.81, specificity 0.58, positive likelihood ratio 1.93, negative likelihood ratio 0.33). The time-dependent analysis of
CRP-ratio of the three patterns (fast response n = 66; slow response n = 81; nonresponse n = 44) was significantly
different between groups (p < 0.001). The ICU mortality rate was considerably different according to the patterns
of CRP-ratio response: fast response 4.8%, slow response 17.3% and nonresponse 36.4% (p < 0.001).
Conclusions: In severe CAP, sequential evaluation of CRP-ratio was useful in the early identification of patients
with poor outcome. The evaluation of CRP-ratio pattern of response to antibiotics during the first week of therapy
was useful in the recognition of the individual clinical evolution.
Introduction
Community-acquired pneumonia (CAP) is a major cause
of death due to infectious diseases in the Western world
[1]. Among hospitalized patients, up to 36% require
admission to the intensive care unit (ICU), and despite
advances in antimicrobial therapy, more than one third
of the patients will die during hospital stay [2-6].
After prescription of antibiotics, the evaluation of the
individual clinical response and the assessment of reso-
lution of pneumonia usually rely on the monitoring of
the same criteria used for clinical diagnosis. Commonly
used variables, such as temperature and white blood cell
count, have a limited value in the assessment of clinical
response to antibiotics [7,8] since both present signifi-
cant improvements late in the course and can be influ-
enced by drugs frequently used in ICU, such as steroids,
antipyretics, or beta blockers.
To overcome these limitations, physicians frequently
use serum biomarkers to assist in the clinical decision-
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making process, namely in the assessment of clinical
response to antibiotic therapy. C-reactive protein (CRP)
is one of these biomarkers and probably the most widely
used [9]. In different infections and clinical settings,
CRP discriminates, early in the clinical course, survivors
from non-survivors. In addition, the course of relative
CRP variations, the CRP ratio, after prescription of anti-
biotic therapy, can be classified in different patterns as
fast response, slow response, and non-response [7,8].
Previous studies have demonstrated that the identifica-
tion of the individual pattern of CRP ratio response to
antibiotic therapy appears to be a reflection of the clini-
cal course of infection independently of other possible
confounders [7,8,10].
The aims of the present study were to evaluate the
course of CRP ratio and identify the patterns CRP ratio
response to antibiotic therapy during the first week in
patients with severe CAP in order to differentiate
between patients with good and poor outcome early in
the clinical course and potentially provide a useful and
easy-to-use tool for antibiotic stewardship.
Materials and methods
Study subjects
We conducted a prospective observational cohort study
in two medical-surgical ICUs at tertiary hospitals (Barra
D’Or Hospital, Rio de Janeiro, Brazil, and Garcia de
Orta Hospital, Almada, Portugal). Patients with severe
CAP that required ICU admission were consecutively
included between November 2001 and December 2002
at Garcia de Orta Hospital and between August 2003
and June 2007 at Barra D’Or Hospital. To perform the
present analysis, the independent databases were
merged. The institutional review boards approved the
study design and waived the need for informed consent.
The present study was strictly observational and did not
interfere in the decision-making process or clinical man-
agement. Patients were treated according to best stan-
dard ICU practice without any reference to the response
patterns of CRP in their daily evaluation.
Study design and definitions
Demographic, clinical, laboratory, and outcome data
were prospectively collected. The Acute Physiology
and Chronic Health Evaluation II (APACHE II) score
was calculated after 24 hours of ICU admission [11].
Severe CAP was diagnosed according to the American
Thoracic Society (ATS) criteria, and the CURB-65
scale - confusion of new onset (defined as an abbre-
viated mental test score of 8 or less), urea of greater
than 7 mmol/L (19 mg/dL), respiratory rate of 30
breaths per minute or greater, systolic blood pressure
of less than 90 mm Hg or diastolic blood pressure of
60 mm Hg or less, and age of at least 65 years - was
used to evaluate its severity [12]. Patients were fol-
lowed until death or hospital discharge. Antimicrobial
therapy was prescribed in accordance with the ATS
guidelines to all patients [12]. Patients with severe
immunosuppression (for example, from solid organ or
bone marrow transplant, HIV infection, or immuno-
suppressive treatment) and tuberculosis were excluded
from the present study.
CRP, arterial oxygen tension/inspiratory oxygen frac-
tion ratio (PaO2/FiO2 ratio), and Sequential Organ Fail-
ure Assessment (SOFA) [13] score were routinely
measured during the first week of ICU stay at day 1
(D1), D3, D5, and D7. The CRP ratio was calculated in
relation to the D1 CRP concentration. Patients were ret-
rospectively classified with a modified version of pre-
viously defined CRP ratio patterns of the response to
antibiotics [7,14]: fast response - when D5 CRP was not
more than 0.4 of D1 CRP concentration; slow response
- when D5 CRP was greater than 0.4 and D7 CRP was
not more than 0.8 of D1 CRP concentration; or non-
response - when D7 CRP was greater than 0.8 of D1
CRP concentration. Comparison between survivors and
non-survivors was performed.
Statistical analysis
Continuous variables are presented as the mean ± stan-
dard deviation unless stated otherwise. Comparisons
between groups were performed by using the parametric
unpaired and paired t test or the non-parametric Mann-
Whitney U test and the Wilcoxon signed-rank test for
continuous variables according to data distribution. The
chi-squared test was used to carry out comparisons
between categorical variables. Time-dependent analysis
of different variables was performed via general linear
model univariate repeated-measures analysis using a
split-plot design approach. Receiver-operating character-
istic curves were drawn for the D5 CRP ratio. The opti-
mal CRP ratio cutoff was defined as the value associated
with the highest sum of sensitivity and specificity (You-
den’s index).
To identify the variables (independent variables) pre-
dicting ICU outcome of severe CAP (dependent vari-
able) during antibiotic therapy, a multivariable logistic
regression model was constructed. Age, sex, APACHE II
score, D1 PaO2/FiO2 ratio, mechanical ventilation, ICU-
acquired infection, septic shock, D5 CRP ratio of greater
than 0.5, and D1 SOFA score were included in the
initial model to control for potential confounding fac-
tors. Backward stepwise variable elimination was then
performed in order to develop the final model, and a P
value of less than 0.05 was a requirement for accep-
tance. Model calibration and discrimination were
assessed by using the Hosmer-Lemeshow goodness-of-
fit test and the c statistic, respectively. Results are
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reported as adjusted odds ratio (AOR) with 95% confi-
dence interval (CI). Data were analyzed by using PASW
version 18.0 for MAC (SPSS, Inc., Chicago, IL, USA).
All statistics were two-tailed, and the significance level
was set at 0.05.
Results
A total of 191 patients with severe CAP requiring ICU
admission were included. The main characteristics of
the study population are presented in Table 1. The ICU
and hospital mortality rates were 21.9% and 24.6%,
respectively. A microbiological diagnosis was established
in 33 patients (17.2%) (Table 2). All patients with micro-
biological diagnosis had initial adequate antibiotic treat-
ment. On ICU admission, 111 patients (58.1%) required
invasive mechanical ventilation.
D1 CRP and CRP ratio course from D1 to D7
At D1, CRP concentration was not significantly differ-
ent between survivors and non-survivors (15.5 versus
14.3 mg/dL, P = 0.91). The course of CRP ratio during
the first week of antibiotic therapy showed a steady
and significant decrease in survivors (P = 0.01). As
early as D3, the CRP ratio of survivors decreased by an
average of 24% but by only 11% in non-survivors (P =
0.106). By D5 of antibiotic therapy, this divergent evo-
lution of CRP ratio was markedly different; the CRP
ratio was 0.46 (P < 0.001) in survivors but remained
elevated in non-survivors, at 0.79 (P = 0.313). The abil-
ity of the CRP ratio by D5 to predict outcome assessed
by the area under the receiver operating characteristic
curve was 0.73 (95% CI = 0.64 to 0.82). By D5, a CRP
concentration of above 0.5 of the initial level was a
marker of poor outcome (sensitivity of 0.81, specificity
of 0.58, positive likelihood ratio of 1.93, and negative
likelihood ratio of 0.33).
In the multivariable analysis, only three variables - D1
SOFA score (per 1-point increment; AOR = 1.20, 95%
CI = 1.06 to 1.37; P = 0.006), D5 CRP ratio of greater
than 0.5 (AOR = 4.47, 95% CI = 1.64 to 12.20; P =
0.003), and mechanical ventilation (AOR = 9.39, 95% CI
= 2.63 to 33.60; P = 0.001) - were independently asso-
ciated with ICU mortality (model n = 175 and goodness
of fit = 0.447).








Age in years 70 (54-81) 77 (64-83) 69 (53-79) 0.03
Male gender, number (percentage) 102 (53.4%) 19 (45.2%) 83 (55.7) 0.29
APACHE II score in points 15 (12-19) 18 (14-23) 15 (11-19) 0.004
CURB-65 in points 3 (3-4) 4 (3-5) 3 (2-4) 0.008
PaO2/FiO2 ratio in mm Hg 244 (172-295) 210 (157-266) 250 (177-300) 0.052
SOFA score in points 5 (3-8) 7 (3.7-10) 4 (3-7) 0.004
Positive blood cultures, number (percentage) 22 (11.5%) 7 (11.9%) 15 (11.4%) 0.99
Invasive mechanical ventilation, number (percentage) 111 (58.1%) 34 (80.9%) 77 (51.6%) 0.0007
Septic shock at ICU admission, number (percentage) 79 (41.3%) 26 (61.7%) 53 (35.5%) 0.0007
COPD, number (percentage) 41 (21.4%) 8 (19%) 33 (22.1%) 0.83
Diabetes, number (percentage) 36 (18.8%) 7 (16.6%) 29 (19.4%) 0.86
Asthma, number (percentage) 10 (5.2%) 2 (4.7%) 8 (5.3%) 0.81
Cardiac failure, number (percentage) 9 (4.7%) 1 (2.3%) 8 (5.3%) 0.69
C-reactive protein in mg/dL 15.3 (7.8-24.2) 14.3 (7.7-24.6) 15.5 (7.9-24.2) 0.91
ICU LOS in days 7 (4-15) 11.5 (5-22.7) 7 (4-13) 0.01
Hospital LOS in days 13 (9-26) 16 (6-36.7) 13 (9-23.5) 0.57
Results are expressed as median (25% to 75% interquartile range) unless stated otherwise. aFor comparisons among survivors and non-survivors. APACHE II,
Acute Physiology and Chronic Health Evaluation II; COPD, chronic obstructive pulmonary disease; CURB-65 scale, confusion of new onset (defined as an
abbreviated mental test score of 8 or less), urea of greater than 7 mmol/L (19 mg/dL), respiratory rate of 30 breaths per minute or greater, systolic blood
pressure of less than 90 mm Hg or diastolic blood pressure of 60 mm Hg or less, and age of at least 65 years; ICU, intensive care unit; LOS, length of stay; PaO2/
FiO2 ratio, arterial oxygen tension/inspiratory oxygen fraction ratio; SOFA, Sequential Organ Failure Assessment.
Table 2 Microorganisms isolated from the 33 (17.2%)
patients with severe community-acquired pneumonia
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CRP ratio patterns of response to antibiotic therapy
Patients with severe CAP were retrospectively divided
according to three patterns of the CRP ratio course dur-
ing antibiotic therapy. Sixty-six (35%) patients were clas-
sified as fast response pattern, 81 (42%) as slow
response, and 44 (23%) as non-response. The time-
dependent analysis of CRP ratio (Figure 1) variations of
the three different patterns was statistically different (P
< 0.001). By D5, the CRP ratios were 0.23, 0.74, and
1.47 in patients exhibiting a fast response, a slow
response, and a non-response pattern, respectively (P <
0.001).
When we analyzed the correlation between the CRP
ratio patterns and outcome, we found marked differ-
ences in ICU mortality rate. Patients with the fast
response, slow response, and non-response patterns pre-
sented ICU mortality rates of 4.6%, 17.3%, and 36.4%,
respectively (P < 0.001) (Figure 1). Similarly, the hospital
mortality was significantly different according to the
CRP ratio pattern: fast response, 9.5%; slow response,
25.9%; and non-response, 43.2% (P = 0.001).
CRP ratio patterns of response and clinical course
The clinical course during antibiotic therapy was moni-
tored with SOFA score and the PaO2/FiO2 ratio. The
time-dependent analysis of the PaO2/FiO2 ratio from D1
to D7 of antibiotic therapy in survivors and non-survi-
vors was significantly different (P < 0.001) but was not
different between the different patterns of CRP ratio (P
= 0.210). However, the SOFA score from D1 to D7 of
antibiotic therapy in survivors and non-survivors was
significantly different (P < 0.001) as well as between the
different patterns of CRP ratio response (P < 0.001)
(Figure 2).
Mechanically ventilated patients with CAP
In the subpopulation of mechanically ventilated patients





Figure 1 Time-dependent analysis of C-reactive protein (CRP) ratio in different patterns of response during first week of antibiotic
therapy. Data are presented as the mean ± standard deviation.
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analysis of CRP ratio was also significantly different
between survivors and non-survivors as well as between
the different patterns of CRP ratio response to antibio-
tics (P = 0.002 and P < 0.001, respectively). In addition,
in this subgroup of patients, the course of PaO2/FiO2
ratio during the first week of antibiotic therapy in the
different patterns of CRP ratio response was not signifi-
cantly different (P = 0.437). However, again, the SOFA
score according to the different patterns of CRP ratio
response during the same time period was significantly
different (P = 0.001).
Discussion
In the present study, we described the patterns of serial
measurements of CRP ratio and its relation with clinical
resolution of severe CAP in a large cohort of patients
requiring intensive care admission. With the resolution
of infection, the concentration of CRP decreases at a
rate that is dependent on its half-life, since this marker
exhibits a first-order elimination kinetics [15]. So the
assessment of relative variations is more informative
about the course of infection than absolute variations
are [9,16]. In our study, survivors showed a continuous
and significant decrease of CRP ratio during the first
week of antibiotic therapy. Conversely, in non-survivors,
CRP ratio remained elevated, and at D5, a CRP ratio of
higher than 0.5 was associated with a fivefold increase
in the risk of death in the ICU. Interestingly, in our
study, patients with the non-response CRP ratio pattern
presented a significantly higher ICU mortality than
patients with fast or slow response patterns. Addition-
ally, the identification of CRP ratio pattern of response
to antibiotics, during the first week of therapy, was use-
ful in the recognition of the individual clinical evolution
of patients with severe CAP.
These data suggest that persistently elevated CRP
values are indicative of poor response to antibiotic ther-





Figure 2 Time-dependent analysis of the Sequential Organ Failure Assessment (SOFA) score during first week of antibiotic therapy in
the different patterns of C-reactive protein (CRP) ratio.
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antibiotic therapy [7,8], the presence of other infectious
complications [17], or a newly developed infection in
another location [9,16]. Several studies have confirmed
that serial measurements of CRP are useful in the moni-
toring of clinical course as well as assessment of patient
outcome in different severe infections. In all of these
studies, survivors by D3 to D4 presented values of CRP
ratio of between 0.5 and 0.8 of the initial value
[7,8,18-23]. This means that, after 72 to 96 hours of
antibiotic therapy, the CRP of survivors decreases by
30% to 50% of the initial concentration. Besides, serial
measurement of CRP allows the identification of various
patterns of response to antibiotic therapy, as previously
described by our group [7].
This concept of patterns of CRP ratio response to
antibiotics has been tested in different clinical settings
and reproduced by different research groups. In a recent
study, Moreno and colleagues [20] studied the value of
daily measurements of CRP in a cohort of 64 patients
with nosocomial pneumonia. Patients were classified
according to the CRP ratio in two groups: ‘good’
response (CRP ratios of lower than 0.67 at D10) and
‘poor’ response (non-response or biphasic response).
The poor-response group (n = 34) had a mortality rate
of 53% in comparison with 20% in the good-response
group (n = 30) (relative risk = 2.65, 95% CI = 1.21 to
5.79; P = 0.01). Significant differences between the two
groups were found on CRP ratios at D4 (P = 0.01).
Also, in a cohort of 891 patients who had community-
acquired sepsis and who were admitted to the ICU,
Povoa and colleagues [19] found that patterns of CRP
ratio response to antibiotics presented a marked correla-
tion with hospital mortality. Patients with a non-
response pattern had a 2.5 times higher probability of
dying in comparison with patients with fast response
(AOR = 2.5, 95% CI = 1.6 to 4.0; P < 0.001). Slow
responders showed a non-significant increase on the
odds of mortality in comparison with the fast respon-
ders (AOR = 1.5, 95% CI = 0.9 to 2.5; P = 0.124). The
results of the present study are in agreement with this
concept in the population of patients with severe CAP.
In all of these studies, the patterns of CRP ratio
response allowed the early identification (between D3
and D4) of patients with poor response to antibiotics
and consequently with poor prognosis. In our study, by
D5, a CRP concentration of above 0.5 of the initial level
was a marker of poor outcome.
The evaluation of changes in organ dysfunction/fail-
ure, assessed by the PaO2/FiO2 ratio and the SOFA
score, could be helpful in the assessment of the effect of
different therapeutic interventions. However, the PaO2/
FiO2 ratio was not helpful in distinguishing between the
different patterns of CRP ratio response during the first
week of antibiotic therapy. The same was true in the
subgroup of mechanically ventilated patients. Similar
results were found in other studies in patients with ven-
tilator-associated pneumonia and bloodstream infection
[7,8].
When we studied the SOFA score from D1 to D7, we
found a significant decrease in survivors in comparison
with non-survivors. Also, patients with CRP ratio pat-
terns of fast or slow response presented a significant
decrease of SOFA score, whereas in patients with non-
response, SOFA score remained almost unchanged.
Similar findings were observed in the subgroup of
mechanically ventilated patients. In our study, we show
a good correlation between CRP ratio course and organ
failure evolution measured by the SOFA score, either
improving or not as well as the rate of improvement,
respectively. In fact, the decrease of CRP ratio by D3
anticipates the decrease in SOFA score, and this could
suggest that CRP is a better marker of resolution of
severe CAP. Similar results were observed in patients
with ventilator-associated pneumonia and bloodstream
infections [7,8,24]. Additionally, the clinical application
of the SOFA score is not as easy and straightforward as
CRP interpretation, since SOFA score calculation
implies the collection of data of several clinical and
laboratorial parameters. So SOFA score determination is
more time-consuming and difficult to perform routinely
at the bedside. Consequently, the identification of the
CRP ratio patterns of response in combination with the
clinical evaluation could become a useful tool with good
potential to reduce the length of antibiotic therapy as
well as to reduce the risks of emergence of resistant
strains and costs of medication, a hypothesis to be
tested in future trials of CRP-guided therapy.
Our study has important strengths. It contained a rea-
sonably large sample collected in two ICUs and evalu-
ated the CRP ratio patterns of response to antibiotics in
patients with severe CAP. However, there are limitations
to the study; namely, it was an observational study.
Also, the data came from two independent databases
and were collected in different periods. As a result, we
cannot exclude the possibility of time-dependent effect
on the results. Most of the diagnoses were made on the
basis of clinical and radiological criteria according to the
ATS criteria, although only 17.2% of the patients were
found to have microbiologically documented pneumo-
nia. In addition, we have no information concerning
antibiotic therapy previous to ICU admission. Besides,
the attending physicians were not blinded to the CRP
results. Finally, in this study, we evaluated only one bio-
marker, namely CRP. So we cannot exclude the possibi-
lity that similar results could be obtained with other
biomarkers.
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Conclusions
Serial evaluation of CRP ratio was useful in the early
identification of patients with severe CAP with a poor
outcome. Besides, the recognition of the patterns of
CRP ratio in patients with severe CAP provided addi-
tional information about the individual clinical course
and this information could significantly influence the
clinical decision-making process at the bedside. In
patients with persistently elevated or rising CRP ratio
(that is, a non-response pattern), an aggressive diagnos-
tic and therapeutic approach should be attempted in
order to prevent further clinical deterioration in an
effort to change the poor associated prognosis. In con-
trast, patients with consistent CRP ratio decrease (that
is, patterns of fast or slow response) usually have an
adequate antibiotic therapy, rapid resolution of infection,
and good prognosis.
Key messages
• Serial evaluation of C-reactive protein (CRP) ratio
is useful in the early identification of patients with
severe community-acquired pneumonia (CAP) with
a poor outcome.
• Recognition of the patterns of CRP ratio in
patients with severe CAP provides information about
the individual clinical course.
• In patients with a non-response pattern, an aggres-
sive diagnostic and therapeutic approach should be
attempted in order to change the poor associated
prognosis.
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